This article is part of the supplement: Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection .

Oral presentation

O111 Global impact of HIV drug resistance

D Pillay

Health Protection Agency, London, UK

corresponding author email

from Ninth International Congress on Drug Therapy in HIV Infection
Glasgow, UK. 9–13 November 2008

Journal of the International AIDS Society 2008, 11(Suppl 1):O1doi:10.1186/1758-2652-11-S1-O1

The electronic version of this abstract is the complete one and can be found online at: http://www.jiasociety.org/content/11/S1/O1

Published:

10 November 2008

© 2008 Pillay; licensee BioMed Central Ltd.

Oral presentation

ART roll-out is bringing many benefits to infected individuals in the resource-poor world. A large number of studies on ART use in the developed world have informed our understanding on the determinants of ART success and implications of failure. However, there are a number of differences between resource-rich and -poor environments which will impact on the nature of HIV drug resistance. Firstly, virological monitoring (viral load and resistance testing) is unlikely to accompany much roll-out. Thus, treatment switch will be guided more by clinical, than virological/immunological criteria. Secondly, increasing use of MTCTP will lead to resistance in infected mothers and children, prior to instigating long term ART. Thirdly, the limited first- and second-line treatment options will impact on the clinical implications of emerging resistance. These three issues, as well as others, will determine the levels of emerging resistance in treated individuals, and thus the degree to which transmission of such resistance will occur. I will review the data on all these issues, and describe some of the surveillance structures in place to monitor rates of resistance.

Have something to say? Post a comment on this article!